In June 2021 Charnwood Molecular was delighted to announce the acquisition of Aurelia Bioscience, an assay development, pharmacological profiling and compound screening provider.
The sector-leading expertise and technology development focus within the team has enhanced Charnwood Molecular’s provision of a world-class integrated drug discovery and development service platform.
Led by co-founders Gary Allenby and Kathy Dodgson the team is now firmly established as Charnwood Molecular’s bioscience division. The group has gone from strength-to-strength, bringing their significant experience of different target classes and the use of cutting-edge technologies to ensure client projects are delivered to time and budget.
In addition there has been a significant increase in size of the team from 7 last June to 14 this year. The team is mostly composed of Ph.D. scientists with experience in a number of areas of disease biology including cancer, metabolic disorders and inflammation.
Contact us to find out how our bioscience division can help you.
